SG52690A1 - Process for the production of biologically active protein (e.g. tgf) - Google Patents

Process for the production of biologically active protein (e.g. tgf)

Info

Publication number
SG52690A1
SG52690A1 SG1996007909A SG1996007909A SG52690A1 SG 52690 A1 SG52690 A1 SG 52690A1 SG 1996007909 A SG1996007909 A SG 1996007909A SG 1996007909 A SG1996007909 A SG 1996007909A SG 52690 A1 SG52690 A1 SG 52690A1
Authority
SG
Singapore
Prior art keywords
tgf
production
biologically active
active protein
beta
Prior art date
Application number
SG1996007909A
Other languages
English (en)
Inventor
Nico Cerletti
David Cox
Gary Kent Mcmaster
Bernd Meyhack
Albert Schmitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG52690A1 publication Critical patent/SG52690A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SG1996007909A 1989-12-06 1990-11-27 Process for the production of biologically active protein (e.g. tgf) SG52690A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898927546A GB8927546D0 (en) 1989-12-06 1989-12-06 Process for the production of biologically active tgf-beta

Publications (1)

Publication Number Publication Date
SG52690A1 true SG52690A1 (en) 1998-09-28

Family

ID=10667491

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996007909A SG52690A1 (en) 1989-12-06 1990-11-27 Process for the production of biologically active protein (e.g. tgf)

Country Status (23)

Country Link
US (2) US5650494A (ja)
EP (2) EP0891985A1 (ja)
JP (1) JP3048061B2 (ja)
KR (1) KR100203230B1 (ja)
AT (1) ATE178616T1 (ja)
AU (1) AU638075B2 (ja)
CA (1) CA2031430C (ja)
DE (1) DE69033040T2 (ja)
DK (1) DK0433225T3 (ja)
ES (1) ES2132066T3 (ja)
FI (1) FI103278B1 (ja)
GB (1) GB8927546D0 (ja)
GR (1) GR3030703T3 (ja)
HU (1) HU218144B (ja)
IE (2) IE904386A1 (ja)
IL (1) IL96549A (ja)
MX (1) MX172600B (ja)
NO (1) NO301768B1 (ja)
NZ (1) NZ236333A (ja)
PH (1) PH31649A (ja)
PT (1) PT96068B (ja)
SG (1) SG52690A1 (ja)
ZA (1) ZA909762B (ja)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
ES2119779T3 (es) * 1990-09-05 1998-10-16 Southern Cross Biotech Pty Ltd Solubilizacion de proteinas en formas activas.
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
US20080139474A1 (en) * 1991-11-04 2008-06-12 David Israel Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
KR100259827B1 (ko) * 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
AU2738392A (en) * 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US6884787B2 (en) * 2001-07-14 2005-04-26 Isis Pharmaceuticals, Inc. Antisense modulation of transforming growth factor-beta 3 expression
DE4243729A1 (de) * 1992-12-23 1994-06-30 Behringwerke Ag Verfahren zur Reaktivierung von gereinigten Membranproteinen
WO1994015968A1 (en) * 1993-01-08 1994-07-21 The Upjohn Company Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein
JP3555952B2 (ja) * 1993-04-30 2004-08-18 バイオグノスティック・ゲゼルシャフト・フュア・バイオモレキュラーレ・ダイアグノスティック・ミット・ベシュレンクテル・ハフツング トランスフォーミング成長因子−β（ＴＧＦ‐β）の免疫抑制効果の治療用アンチセンス−オリゴヌクレオチド類
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
EP0670733A1 (en) * 1993-09-29 1995-09-13 Alcon Laboratories, Inc. Compositions containing growth factors and antiplastic agents
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
AU689184B2 (en) * 1993-12-07 1998-03-26 Genetics Institute, Llc BMP-12, BMP-13 and tendon-inducing compositions thereof
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
TW440566B (en) * 1994-07-25 2001-06-16 Novartis Ag Novel process for the production of biologically active dimeric protein
TW517059B (en) 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
CA2194177A1 (en) * 1994-07-25 1996-02-08 Jui Yoa Chang Process for folding of proteins like recombinant hirudin or epidermal growth factor
US7235527B2 (en) * 1995-04-19 2007-06-26 Biopharm Gesellschaft Zur Biotechnologieschen Entwicklung Von Pharmaka Mbh Protein and process for producing the same
US5714371A (en) * 1995-05-12 1998-02-03 Schering Corporation Method for refolding insoluble aggregates of hepatitis C virus protease
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
US6352972B1 (en) * 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth
US6040431A (en) 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)
CA2235223A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
EP0943690B1 (en) * 1995-12-21 2006-11-29 Ajinomoto Co., Inc. Method for refolding human activin a
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
JP2000501744A (ja) * 1996-01-22 2000-02-15 クリエイティブ バイオモレキゥルズ，インコーポレーテッド モルホゲン類似体およびその製法
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US7811793B2 (en) 1996-12-25 2010-10-12 Biopharma Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Process for preparing purified active monomer of bone-derived factor
US7723473B2 (en) 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
US6500920B1 (en) * 1997-06-19 2002-12-31 St. Louis University Inhibitor of transforming growth factor β and A method of inhibiting the biological effects of transforming growth factor
ATE220564T1 (de) 1997-08-14 2002-08-15 Sulzer Innotec Ag Zusammensetzung und vorrichtung zur reparatur von knorpelgewebe in vivo bestehend aus nanokapseln mit osteoinduktiven und/oder chondroinduktiven faktoren
US20020052026A1 (en) 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
DE19749259A1 (de) * 1997-11-07 1999-05-12 Dade Behring Marburg Gmbh Verfahren zur Herstellung von funktionalem rekombinantem Gewebsfaktor
BR9907691B1 (pt) * 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
US6677432B1 (en) 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
JP3762222B2 (ja) 1998-10-07 2006-04-05 ストライカー・コーポレーション 改変型ＴＧＦ−βスーパーファミリータンパク質
US6846906B1 (en) 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
US7087577B2 (en) 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
EP1142908A4 (en) * 1999-01-07 2002-05-22 Takeda Chemical Industries Ltd PROCESS FOR PRODUCING ACTIVATED PROTEINS
US6727224B1 (en) * 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
DE19906096A1 (de) 1999-02-13 2000-08-17 Walter Sebald Protein mit einem Heparin-bindenden Epitop
WO2000065521A2 (en) 1999-04-23 2000-11-02 Massachusetts Institute Of Technology System and method for polymer notation
DE19944626A1 (de) * 1999-09-17 2001-03-22 Knoell Hans Forschung Ev Verfahren zur Herstellung von dimeren, biologisch aktiven knochenmorphogenetischen Proteinen
WO2001066772A2 (en) 2000-03-08 2001-09-13 Massachusetts Institute Of Technology Heparinase iii and uses thereof
DE10026713A1 (de) * 2000-05-30 2001-12-06 Walter Sebald Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
US7081240B1 (en) * 2000-06-28 2006-07-25 Zimmer Orthobiologics, Inc. Protein mixtures for wound healing
CA2422059C (en) 2000-09-12 2012-05-15 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
CA2423469A1 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
EE200300408A (et) 2001-02-23 2003-12-15 Immunex Corporation Aktiivsete valkude saagise suurendamine
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
EP1399023B1 (en) * 2001-06-01 2008-04-30 Wyeth COMPOSITIONS FOR SYSTEMIC ADMINISTRATION OF SEQUENCES ENCODING BONE MORPHOGENETIC PROTEINS& x9;
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP1432431B1 (en) 2001-10-04 2017-05-10 Genetics Institute LLC Methods and compositions for modulating interleukin-21 activity
US7232802B2 (en) 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
ATE358681T1 (de) * 2002-02-05 2007-04-15 Geymonat Spa Verfahren zur rekombinanten herstellung von plazenta wachstumsfaktor
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
CA2495222A1 (en) * 2002-08-13 2004-02-19 Wyeth Peptides as solubilizing excipients for transforming growth factor ss proteins
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
US7074412B2 (en) 2003-01-30 2006-07-11 The University Of Zurich Pharmaceutical composition
NZ543365A (en) 2003-04-18 2009-02-28 Biogen Idec Inc Polymer-conjugated glycosylated neublastin
PL1675608T3 (pl) 2003-09-12 2007-11-30 Wyeth Corp Stałe fosforanowo wapniowe pałeczki do wstrzyknięć dla dostarczania białek osteogennych
ES2403357T3 (es) 2003-12-11 2013-05-17 Isto Technologies Inc. Sistema de cartílago particulado
US8722862B2 (en) * 2004-08-19 2014-05-13 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
EA013565B1 (ru) * 2004-08-19 2010-06-30 Байоджен Айдек Ма Инк. Варианты полипептидов нейбластина, способы их получения и их применение
WO2006081379A1 (en) * 2005-01-26 2006-08-03 Wyeth Use of sfrps as markers of bmp activity
CN101160528A (zh) 2005-02-14 2008-04-09 惠氏公司 Il17-f在诊断和治疗气道炎症中的用途
EP2322553A3 (en) 2005-02-14 2011-11-16 Wyeth LLC Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
JP2008534607A (ja) * 2005-03-30 2008-08-28 ワイス Ｂｍｐを投与することによって毛髪の成長を刺激するための方法
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
GB0514262D0 (en) * 2005-07-12 2005-08-17 Renovo Ltd Promotion of epithelial regeneration
WO2007014170A2 (en) * 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Compositions and methods for protein deaggregation
GB0516204D0 (en) * 2005-08-06 2005-09-14 Riotech Pharmaceuticals Ltd Methods
JP5292533B2 (ja) 2005-08-26 2013-09-18 ジンマー・インコーポレイテッド インプラントおよび関節疾患の治療、置換および治療方法
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US7582609B2 (en) * 2006-03-01 2009-09-01 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
EP1993590B1 (en) * 2006-03-01 2013-12-25 Biogen Idec MA Inc. Compostions and methods for administering gdnf ligand family proteins
GB0604966D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Medicaments and proteins
GB0604938D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
GB0604964D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Protein folding
TWI476207B (zh) * 2006-07-14 2015-03-11 Genentech Inc 重組蛋白之再摺疊
GB0617816D0 (en) * 2006-09-11 2006-10-18 Renovo Ltd Nucleic acids and methods of protein expression
SI2078071T1 (sl) 2006-11-08 2015-05-29 Wyeth Llc Racionalno zasnovana gojišča za celično kulturo
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
WO2008128075A1 (en) 2007-04-12 2008-10-23 Isto Technologies, Inc. Compositions and methods for tissue repair
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
EP2188371B1 (en) 2007-08-09 2017-12-20 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
WO2009029656A1 (en) 2007-08-27 2009-03-05 Auxagen, Inc. METHODS FOR INHIBITING TGF-β
US8487006B2 (en) 2008-09-16 2013-07-16 Auxagen, Inc. Method of enhancing TGF-β signalling
US8494140B2 (en) * 2008-10-30 2013-07-23 Centurylink Intellectual Property Llc System and method for voice activated provisioning of telecommunication services
EP2350130B1 (en) 2008-10-31 2018-10-03 Wyeth LLC Purification of acidic proteins using ceramic hydroxyapatite chromatography
EP3366692A1 (en) * 2009-06-22 2018-08-29 Amgen, Inc Refolding proteins using a chemically controlled redox state
EP2445924B2 (en) 2009-06-25 2023-12-13 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
KR100991203B1 (ko) 2010-05-10 2010-11-01 심영복 골형성 단백질의 정제 방법
US20140148387A1 (en) 2010-09-01 2014-05-29 Masahiro Nagaya Freeze-dried recombinant human bone morphogenetic protein-2 preparation
SG11201404603SA (en) * 2012-02-10 2014-10-30 Japanic Corp Cosmetic product or skin regeneration promoter comprising nonhuman stem cell culture supernatant as starting material, and method for ion introduction for protein
DK2879691T3 (da) 2012-08-06 2019-06-11 Biogen Ma Inc Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
WO2018121703A1 (en) 2016-12-30 2018-07-05 Biogend Therapeutics Co., Ltd. Recombinant polypeptides, compositions, and methods thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU76981A (en) * 1980-03-27 1983-09-30 Lilly Co Eli Process for bonding the a-chain of insulin or insulin analogues and the b-chain of insulin or insulin analogues in order to obtain insulin or insulin analogues
GR79124B (ja) * 1982-12-22 1984-10-02 Genentech Inc
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
WO1984004924A1 (en) * 1983-06-03 1984-12-20 Us Commerce Purified transforming growth factor-beta derived from human platelets and placentas
EP0154434B1 (en) * 1984-02-17 1993-01-27 Genentech, Inc. Human transforming growth factor and precursor or fragment thereof, cells, dna, vectors and methods for their production, compositions and products containing them, and related antibodies and diagnostic methods
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4731440A (en) * 1985-02-22 1988-03-15 Monsanto Company Method of somatotropin solubilization using dimethylsulfone and naturation
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
GB8508340D0 (en) * 1985-03-29 1985-05-09 Creighton T E Production of protein
EP0208539A3 (en) * 1985-07-11 1988-08-03 Repligen Corporation Folding disulfide-cross-linkable proteins
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
NZ222168A (en) * 1986-10-20 1991-05-28 Oncogene Science Inc Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
PT86144B (pt) * 1986-11-17 1990-08-31 Sandoz Sa Processo para a preparacao de uma proteina tendo actividade semelhante a factor g-tsf humano e de composicoes farmaceuticas que o contem
FI100106B (fi) * 1986-12-05 1997-09-30 Novartis Ag Menetelmä plasminogeenin yksisäikeisen yhdistelmäaktivaattorin valmist amiseksi
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
EP0368857B1 (en) * 1987-05-11 1997-08-06 Chiron Corporation Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
US5162507A (en) * 1987-05-11 1992-11-10 Cetus Corporation Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
AU626524B2 (en) * 1987-05-29 1992-08-06 Bristol-Myers Squibb Company Cloning and expression of simian transforming growth factor- beta 1
US4985544A (en) * 1987-08-04 1991-01-15 Kyowa Hakko Kogyo Co., Ltd. Process for renaturing fish growth hormone
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5144006A (en) * 1991-06-13 1992-09-01 The Rockefeller University Oxidative folding of peptide and protein substrates using hydrocarbon sulfoxides
AU2738392A (en) * 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors

Also Published As

Publication number Publication date
HUT56880A (en) 1991-10-28
DK0433225T3 (da) 1999-10-25
NO905264D0 (no) 1990-12-05
FI103278B (fi) 1999-05-31
PH31649A (en) 1999-01-12
GB8927546D0 (en) 1990-02-07
FI905956A (fi) 1991-06-07
PT96068A (pt) 1991-09-30
EP0433225A1 (en) 1991-06-19
AU638075B2 (en) 1993-06-17
KR910012240A (ko) 1991-08-07
NO301768B1 (no) 1997-12-08
EP0891985A1 (en) 1999-01-20
JP3048061B2 (ja) 2000-06-05
CA2031430C (en) 2003-05-27
NO905264L (no) 1991-06-07
ZA909762B (en) 1991-08-28
MX172600B (es) 1994-01-03
FI103278B1 (fi) 1999-05-31
IL96549A0 (en) 1991-09-16
PT96068B (pt) 1998-02-27
CA2031430A1 (en) 1991-06-07
ATE178616T1 (de) 1999-04-15
AU6701890A (en) 1991-06-13
HU908084D0 (en) 1991-06-28
FI905956A0 (fi) 1990-12-03
DE69033040T2 (de) 1999-09-09
IL96549A (en) 2000-10-31
DE69033040D1 (de) 1999-05-12
GR3030703T3 (en) 1999-11-30
NZ236333A (en) 1992-03-26
US5650494A (en) 1997-07-22
EP0433225B1 (en) 1999-04-07
ES2132066T3 (es) 1999-08-16
US5922846A (en) 1999-07-13
IE990992A1 (en) 2000-12-13
JPH03191791A (ja) 1991-08-21
HU218144B (hu) 2000-06-28
IE904386A1 (en) 1991-06-19
KR100203230B1 (ko) 1999-06-15

Similar Documents

Publication Publication Date Title
GR3030703T3 (en) Process for the production of biologically active protein (e.g. TGF)
PH31617A (en) Novel thienylcarboxylates of amino alcohols, theirquaternary products and use of these compounds.
EP0328251A3 (en) 2-(2-hydroxy-3-phenoxypropylamino)ethylphenoxyacetamides and processes and intermediates for their preparation
HU903961D0 (en) Process for producing 11-beta-aryl-4-oestrenes and pharmaceutical preparatives containing these compounds
EP0229016A3 (en) Interleukin-2 compositions
IL80562A0 (en) Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it
EP0288758A3 (en) Dihydropyridinamides, process for their preparation and their use in medicines
ZA878249B (en) Method and therapeutic compositions for the treatment of bleeding disorders
FR2635527B1 (fr) Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
GR3007995T3 (ja)
HU9200400D0 (en) Cinurenic acid derivatives, process for producing them and pharmaceutical compositions containing them
ATE85893T1 (de) Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
ATE53384T1 (de) 3-mercapto-2-oxo-1-pyrrolidinessigsaeurederivate verfahren zur herstellung und pharmazeutische zusammensetzungen die sie enthalten.